BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines REVLIMID (lenalidomide by Year
REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M)
BeOne Medicines REVLIMID (lenalidomide: $36M in FY2024, down 52.6% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-27) ↗
Reported in Form 10-Q / 10-K Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | REVLIMID (lenalidomide — BMS/Celgene China Partnered) ($M, FY18–FY24) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 36 | -52.6% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 76 | -3.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 79 | +12.7% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 70.1 | +47.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 47.4 | -39.2% | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 78 | +40.8% | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 55.4 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines REVLIMID (lenalidomide ($M), annual FY2018–FY2024 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-revlimid
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.